RMTG Expands to Colombia in Latin American Market Push

Regenerative Medical Technology Group, Inc. (RMTG) has expanded its commercial footprint in Latin America, announcing the start of local commercial activities in Colombia. This move follows similar steps in Peru and Brazil, marking the company’s third significant market in the region.

According to a press release, RMTG’s Cellgenic division has begun establishing a presence in Colombia by setting up local representation and developing relationships with physicians and medical providers. These initial steps are part of a broader strategy to build a network that will support the commercial launch of the company’s biologics and cellular products.

The expansion into Colombia is part of RMTG’s ongoing efforts to grow its international operations. The company’s CEO, David Christensen, stated, "Colombia is a strategic market for us, following our successful commercial arrangements in Peru and Brazil. We will proceed in permitted channels and will report any significant developments in our SEC filings."

RMTG operates through its wholly owned subsidiary, Global Stem Cells Group, which develops and distributes cellular products, biologics, and related items to physicians and clinics in permitted international markets. The company is subject to various regulatory requirements and faces ongoing challenges, including its ability to form local operations, comply with Colombian regulatory, import, and professional-licensing rules, and address financial uncertainties.

Christensen added, "We expect the process in Colombia, like in other international markets, to involve time for licensing, staffing, import logistics, and physician onboarding. We are not providing revenue or physician count guidance at this time."

While RMTG’s Cellgenic division has held physician-education programs in Bogotá, these events are separate from product registration and do not establish a commercial network or product sales. The company remains focused on the development and distribution of its products in permitted markets, adhering to local regulatory requirements.

RMTG faces multiple risks, including the uncertainty of its going concern status, limited liquidity, substantial debt obligations, and potential dilution from existing and future equity or convertible instruments. Despite these challenges, the company continues to pursue growth opportunities in Latin America and other international markets.

In summary, RMTG’s expansion into Colombia is a step toward further diversifying its international presence, while the company remains mindful of the regulatory and operational hurdles associated with entering new markets.